KalVista Pharmaceuticals
Operating Status: Acquired Subsidiary
KalVista Pharmaceuticals develops and commercializes protease inhibitors for unmet medical needs in the US and UK.
Founded
2004KalVista Pharmaceuticals develops and commercializes protease inhibitors for unmet medical needs in the US and UK.
KalVista Pharmaceuticals, founded with a mission to address significant unmet medical needs, focuses on the discovery, development, and commercialization of small molecule protease inhibitors. The company's primary market is the United States and the United Kingdom, where it aims to transform the treatment landscape for hereditary angioedema (HAE) through innovative, orally-delivered medicines. KalVista is committed to empowering individuals to live beyond the challenges of their diseases.
Notable affiliated individuals include experienced scientists and industry leaders who drive the company's research and development efforts. KalVista has secured investments from prominent venture capital firms, bolstering its financial stability and growth potential. Key achievements include advancing several promising candidates in clinical trials, positioning the company as a leader in HAE treatment innovation. The overall impact of KalVista Pharmaceuticals lies in its potential to significantly improve the quality of life for patients with HAE through groundbreaking therapeutic options.
Companies similar to KalVista Pharmaceuticals include Rigel Pharmaceuticals, Alexion Pharmaceuticals, Gilead Sciences and Enanta Pharmaceuticals.
KalVista Pharmaceuticals was founded in 2004.
KalVista Pharmaceuticals' headquarters is located in Cambridge, MA, US.
As of Apr 29, 2026, KalVista Pharmaceuticals has disclosed funding of $297.7M (USD). Undisclosed round amounts are excluded.
Enanta Pharmaceuticals
enanta.com
